In animal studies, JH scientists have successfully prevented the development of atherosclerosis, the main cause of heart attacks and strokes and the number-one cause of death among humans
- Johns Hopkins scientists have halted the development of atherosclerotic heart disease in animals by blocking the activity of a sugar-and-fat molecule residing in the membranes of cells.
- Using a widely available man-made compound called D-PDMP, the researchers prevented the buildup of fatty plaque and calcium deposits inside the blood vessels of mice and rabbits fed a high-fat, cholesterol-laden diet.
- Treatment with D-PDMP appears to work by altering a range of biological glitches that affect the body’s ability to properly use, transport and purge itself of cholesterol — the fatty substance that accumulates inside vessels and fuels heart disease.
Working with mice and rabbits, Johns Hopkins scientists have found a way to block abnormal cholesterol production, transport and breakdown, successfully preventing the development of atherosclerosis, the main cause of heart attacks and strokes and the number-one cause of death among humans. The condition develops when fat builds inside blood vessels over time and renders them stiff, narrowed and hardened, greatly reducing their ability to feed oxygen-rich blood to the heart muscle and the brain.
In a series of experiments, described April 7 in the journal Circulation, the Johns Hopkins team says it identified and halted the action of a single molecular culprit responsible for a range of biological glitches that affect the body’s ability to properly use, transport and purge itself of cholesterol — the fatty substance that accumulates inside vessels and fuels heart disease.
The offender, the researchers say, is a fat-and-sugar molecule called glycosphingolipid, or GSL, which resides in the membranes of all cells, and is mostly known for regulating cell growth. Results of the experiments, the scientists say, reveal that this very same molecule also regulates the way the body handles cholesterol.
The Johns Hopkins team used an existing man-made compound called D-PDMP to block the synthesis of the GSL molecule, and by doing so, prevented the development of heart disease in mice and rabbits fed a high-fat, cholesterol-laden diet. The findings reveal that D-PDMP appears to work by interfering with a constellation of genetic pathways that regulate fat metabolism on multiple fronts — from the way cells derive and absorb cholesterol from food, to the way cholesterol is transported to tissues and organs and is then broken down by the liver and excreted from the body.
“Current cholesterol-lowering medications tackle the problem on a single front — either by blocking cholesterol synthesis or by preventing the body from absorbing too much of it,” says lead investigator Subroto Chatterjee, Ph.D., a cardio-metabolic expert at the Johns Hopkins Children’s Center. “But atherosclerosis is a multi-factorial problem that requires hitting the abnormal cholesterol cycle at many points. By inhibiting the synthesis of GSL, we believe we have achieved exactly that.”
Specifically, the experiments showed that treatment with D-PDMP led to:
- a drop in the animals’ levels of so-called bad cholesterol or low-density lipoprotein, LDL;
- a drop in oxidized LDL, a particularly virulent form of fat that forms when LDL encounters free radicals. Oxidized LDL easily sticks to the walls of blood vessels, where it ignites inflammation, damaging the vessel walls and promoting the growth of fatty plaque;
- a surge in good cholesterol or high-density lipoprotein, HDL, known to counteract the effects of LDL by mopping it up; and
- a significant drop in triglycerides, another type of plaque-building fat.
The treatment also prevented fatty plaque and calcium deposits from building up inside the animals’ vessels. These effects were observed in animals on a daily D-PDMP treatment even though they ate a diet made up of 20 percent triglycerides — the human equivalent of eating a greasy burger for breakfast, lunch and dinner. In addition, the researchers say, D-PDMP appears to precision-target the worst byproducts of aberrant cell growth signaling, such as oxidized LDL and the activity of certain chemicals that fuel vessel inflammation, without altering cell growth itself.
D-PDMP, which is already widely used in basic research to experimentally block and study cell growth and other basic cell functions, is deemed safe in animals, the investigators say. For example, animals in the current study had no side effects even when given D-PDMP doses 10 times higher than the minimum effective dose, the study found. The research team is currently designing a compound drug with D-PDMP, which they soon plan to test in other animals and, eventually, in humans.
Mice used in the experiments were genetically engineered to lack a protein essential in the breakdown of fats and thus were predisposed to atherosclerosis. The researchers fed the animals a high-fat diet over the course of several months, but also gave a third of the animals a low-dose of D-PDMP. They gave a double dose of the same inhibitor to another third and placebo to the rest.
When scientists measured the thickness of the animals’ aortas — the body’s largest vessel and one that carries blood from the heart to the rest of the body — they found striking differences among the groups. As expected, the aortas of mice that got placebo had grown thicker from the accumulation of fat and calcium deposits inside them. The aortas of mice on low-dose D-PDMP, however, were significantly thinner with little to no obstruction. To the researchers’ surprise, Chatterjee says, mice eating high-fat foods and treated with high-dose D-PDMP had nearly pristine arteries free of obstruction, indistinguishable from those of healthy mice.
The Latest on: Atherosclerosis
via Google News
The Latest on: Atherosclerosis
- Global Cardiac Biomarkers Market: Latest Global Insights, Growth Factors, Challenges and Industry Trends 2019-2025on November 29, 2019 at 9:16 am
Based on the location of testing, the sub-markets include point of care testing and laboratory testing. By application, the market is categorized into myocardial infarction, congestive heart failure, ...
- Targeting macrophage immunometabolism to prevent atherosclerosison November 29, 2019 at 8:14 am
Di Gioia and colleagues report on how the oxidized phospholipid oxPAPC alters metabolism in macrophages via glutamine and oxaloacetate, thus boosting production of the cytokine IL-1β and promoting ...
- Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic miceon November 29, 2019 at 2:22 am
Despite recent advances in the understanding of its pathophysiology and therapy, diabetes continues to be a major risk factor for the development of atherosclerosis and its complications such as ...
- Hardening of the arteries: Platelets, inflammation and a rogue protein conspire against the hearton November 26, 2019 at 6:42 am
The Lipid Hypothesis of coronary artery disease has long held that a high level of cholesterol is the causative factor of atherosclerosis, but a group of New York scientists is making a powerful case ...
- Atherosclerosis: Scientists identify new protein target in immune cellson November 1, 2019 at 8:29 am
The inflammatory condition atherosclerosis, where fatty, waxy deposits build up in arteries, raises the risk of stroke, heart attack, and cardiovascular disease. Now, using mice and human samples, ...
- Myeloid Tribbles 1 induces early atherosclerosis via enhanced foam cell expansionon October 30, 2019 at 11:18 am
1 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. 2 Division of Cardiology, Department of Medicine, Columbia University ...
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosison October 22, 2019 at 10:44 am
Atherosclerosis is a disease in which plaque build-up results in thickening and hardening of the walls of the arteries. These structural changes can lead to a reduction of blood flow to the brain and ...
- Good Cholesterol Counters Atherosclerosis in Mice with Diabeteson October 20, 2019 at 5:00 pm
NEW YORK: Increasing levels of a simplified version of good cholesterol reversed disease in the blood vessels of mice with diabetes, a new study finds. Published online in the journal Circulation on ...
- ‘Good’ cholesterol counters atherosclerosis in mice with diabeteson September 30, 2019 at 5:51 am
Published online in the journal Circulation on September 30, the study results revolve around atherosclerosis, a condition where high levels of cholesterol cause “plaques” to form in vessel walls, ...
- Mummies show atherosclerosis was prevalent in ancient timeson September 24, 2019 at 2:16 pm
They are thought to be from the period 2000 BC to 1000 AD. The study looked for any evidence that these people had suffered arterial damage due to atherosclerosis. This is a term that refers to the ...
via Bing News